[Product Promotion] TIGIT Target Cell Screening Model

TIGIT (T cell immunoreceptor withIg and ITIM domain, also known as WUCAM, Vstm3, VSIG9) is a receptor of the Ig superfamily, which plays a key role in limiting adaptability and innate immunity. It consists of an extracellular immunoglobulin variable region (IgV) domain, a type 1 transmembrane domain, and a classical immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoglobulin tyrosine tail (ITT) motif Composition of intracellular domains. TIGIT is generally expressed in lymphocytes, especially in activated CD8+T and CD4+T cells, natural killer (NK) cells, regulatory T cells (Tregs) and follicular helper T cells. TIGIT participates in a complex regulatory network involving multiple IRs (for example, CD96/TACTILE, CD112R/PVRIG), a competitive costimulatory receptor (DNAM-1/CD226) and multiple ligands (for example, CD155 (PVR) /NECL-5), CD112 (Nectin-2/PVRL2)).

Among them, CD155 is the high-affinity ligand of TIGIT. TIGIT can competitively bind to CD155 with DNAM-1. Once CD155, which is highly expressed on the tumor surface, binds to TIGIT on the surface of NK and T cells, the killing effect of NK and T cells on tumor cells is affected. Will be suppressed. Of course, CD112 can also bind to TIGIT, but the affinity is much weaker. All in all, blocking the combination of TIGIT and CD155 will block the immunosuppressive function of this pathway. At the same time, DNAM-1 will competitively bind to CD155 and activate the immune activation pathway.

TIGIT is a promising target for tumor immunotherapy, especially in combination with PD-1 blockers. We can provide drug target cell lines related to TIGIT research. Welcome to consult and understand.

 TIGIT/NFAT-Luc/Jurkat RQP74020

Figure 3. Dose response of anti-TIGIT neutralizing antibody in TIGIT/NFAT-Reporter Jurkat cell line (C26) with CD155/TCR activator-CHO, the EC50 was 1.24μg/ml.